Serum fibroblast growth factor 21 is predictive of combined cardiovascular morbidity and mortality in patients with type 2 diabetes at a relatively short-term follow-up

Diabetes Research and Clinical Practice

Volumn 101, Issue 2, 2013, Pages 194-200

  Lenart Lipinska M ^a   Matyjaszek Matuszek, B ^a   Gernand, W ^b   Nowakowski, A ^a   Solski, J ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b Medical Laboratory LOMA   (Poland)

Author keywords

Cardiovascular morbidity; Cardiovascular mortality; Cardiovascular risk; Fibroblast growth factor 21; Type 2 diabetes

Indexed keywords

FIBROBLAST GROWTH FACTOR 21; INSULIN;

ADULT; AGED; ARTICLE; BIOCHEMISTRY; BODY MASS; CARDIOVASCULAR DISEASE; DISEASE DURATION; ELISA KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; INSULIN TREATMENT; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT REFERRAL; PREDICTIVE VALUE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SEX DIFFERENCE;

EID: 84881263662     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2013.04.010     Document Type: Article

References (31)

1. Yusuf S., Hawken S., Ounpuu S., Dans T., Avezum A., Lanas F., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364:937-952.
2. Ma W.Y., Li H.Y., Pei D., Hsia T.L., Lu K.C., Tsai L.Y., et al. Variability in hemoglobin A1c predicts all-cause mortality in patients with type 2 diabetes. J Diabetes Complications 2012, 26:296-300.
3. Retnakaran R., Zinman B., Connelly P.W., Harris S.B., Hanley A.J. Nontraditional cardiovascular risk factors in pediatric metabolic syndrome. J Pediatr 2012, 148:176-182.
4. Chughtai H.L., Morgan T.M., Hamilton C.A., Charoenpanichkit C., Ding J., Brinkley T.E., et al. Intraperitoneal fat is associated with thickening of the thoracic aorta in individuals at high risk for cardiovascular events. Obesity (Silver Spring) 2011, 19:1784-1790.
5. Lindberg S., Pedersen S.H., Møgelvang R., Bjerre M., Frystyk J., Flyvbjerg A., et al. Usefulness of adiponectin as a predictor of all cause mortality in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Am J Cardiol 2012, 109:492-496.
6. Kharitonenkov A., Shiyanova T.L., Koester A., Ford A.M., Micanovic R., Galbreath E.J., et al. FGF-21 as a novel metabolic regulator. J Clin Invest 2005, 115:1627-1635.
7. Nishimura T., Nakatake Y., Konishi M., Itoh N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta 2000, 1492:203-206.
8. Ogawa Y., Kurosu H., Yamamoto M., Nandi A., Rosenblatt K.P., Goetz R., et al. BetaKlotho is required for metabolic activity of fibroblast growth factor 21. Proc Natl Acad Sci U S A 2007, 104:7432-7437.
9. Badman M.K., Koester A., Flier J.S., Kharitonenkov A., Maratos-Flier E. Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis. Endocrinology 2009, 150:4931-4940.
10. Kharitonenkov A., Wroblewski V.J., Koester A., Chen Y.F., Clutinger C.K., Tigno X.T., et al. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 2007, 148:774-781.
11. Zhang X., Yeung D.C., Karpisek M., Stejskal D., Zhou Z.G., Liu F., et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 2008, 57:1246-1253.
12. Wang B., Yang G., Yang M., Liao Y., Li Z., Boden G., et al. Mitiglinide treatment may decreases plasma fibroblast growth factor-21 levels in individuals with new-onset T2DM. Cytokine 2012, 57:300-303.
13. Chen W.W., Li L., Yang G.Y., Li K., Qi X.Y., Zhu W., et al. Circulating FGF-21 levels in normal subjects and in newly diagnosed patients with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2008, 116:65-68.
14. Li X., Fan X., Ren F., Zhang Y., Shen C., Ren G., et al. Serum FGF21 levels are increased in newly diagnosed type 2 diabetes with nonalcoholic fatty liver disease and associated with hsCRP levels independently. Diabetes Res Clin Pract 2011, 93:10-16.
15. Lin Z., Zhou Z., Liu Y., Gong Q., Yan X., Xiao J., et al. Circulating FGF21 levels are progressively increased from the early to end stages of chronic kidney diseases and are associated with renal function in Chinese. PLoS ONE 2011, 6:e18398.
16. Lin Z., Wu Z., Yin X., Liu Y., Yan X., Lin S., et al. Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile. PLoS ONE 2010, 5:e15534.
17. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
18. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
19. National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002, 39:S1-S266.
20. Chavez A.O., Molina-Carrion M., Abdul-Ghani M.A., Folli F., DeFronzo R.A., Tripathy D. Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care 2009, 32:1542-1546.
21. Li H., Fang Q., Gao F., Fan J., Zhou J., Wang X., et al. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J Hepatol 2010, 53:934-940.
22. Berglund E.D., Li C.Y., Bina H.A., Lynes S.E., Michael M.D., Shanafelt A.B., et al. Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity. Endocrinology 2009, 150:4084-4093.
23. Fisher F.M., Chui P.C., Antonellis P.J., Bina H.A., Kharitonenkov A., Flier J.S., et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 2010, 59:2781-2789.
24. Chen C., Cheung B.M., Tso A.W., Wang Y., Law L.S., Ong K.L., et al. High plasma level of fibroblast growth factor 21 is an independent predictor of type 2 diabetes: a 5.4-year population-based prospective study in Chinese subjects. Diabetes Care 2011, 34:2113-2115.
25. Baker W.L., Talati R., White C.M., Coleman C.I. Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis. Diabetes Res Clin Pract 2010, 87:98-107.
26. McEwen L.N., Kim C., Karter A.J., Haan M.N., Ghosh D., Lantz P.M., et al. Risk factors for mortality among patients with diabetes: the Translating Research Into Action for Diabetes (TRIAD) Study. Diabetes Care 2007, 30:1736-1741.
27. Saleh N., Petursson P., Lagerqvist B., Skúladóttir H., Svensson A., Eliasson B., et al. Long-term mortality in patients with type 2 diabetes undergoing coronary angiography: the impact of glucose-lowering treatment. Diabetologia 2012, 55:2109-2117.
28. Carnethon M.R., De Chavez P.J., Biggs M.L., Lewis C.E., Pankow J.S., Bertoni A.G., et al. Association of weight status with mortality in adults with incident diabetes. JAMA 2012, 308:581-590.
29. Verhagen S.N., Wassink A.M., van der Graaf Y., Gorter P.M., Visseren F.L. Insulin resistance increases the occurrence of new cardiovascular events in patients with manifest arterial disease without known diabetes. The SMART study. Cardiovasc Diabetol 2011, 10:100. SMART Study Group.
30. Alssema M., Dekker J.M., Nijpels G., Stehouwer C.D., Bouter L.M., Heine R.J., et al. Proinsulin concentration is an independent predictor of all-cause and cardiovascular mortality: an 11-year follow-up of the Hoorn Study. Diabetes Care 2005, 28:860-865.
31. Yang M., Dong J., Liu H., Li L., Yang G. Effects of short-term continuous subcutaneous insulin infusion on fasting plasma fibroblast growth factor-21 levels in patients with newly diagnosed type 2 diabetes mellitus. PLoS ONE 2011, 6:e26359.